ISSAR Pharma

Home       About Us      Our History

We are proud to reach a turning point in the world of science like never before.

Ram Isanaka-FOUNDED ISSAR PHARMACEUTICALS-to develop new peptide molecules addressing the unmet healthcare needs.

ISSAR conducted the FIRST HUMAN CLINICAL TRIALS FOR MELGAIN (phase 1). ISSAR was the first and the only company to have conducted phase 1 clinical trial in India since independence.

ISSAR commercialised the first ever peptide solution for Vitiligo.

MELGAIN was launched into the market for the treatment of VITILIGO.

ISSAR received NOC to conduct Phase 1 and Phase 2 trials from DCGI.

ISSAR pharmaceuticals established their state-of-the-art, FDA-compliant, 62000 sq ft., manufacturing facility at Genome Valley, Hyderabad, India.

Successfully completed Phase 1 clinical trial for cancers (solid tumors).

ISSAR successfully completed phase III clinical trials for BURN WOUNDS treatment.

ISSAR got permission to manufacture finished formulation of a new drug for the treatment of burn wounds

ISSAR got permission to manufacture and market burn wound product.


In the News

ISSAR Pharma Announces Out-Licensing of Its Peptide-Based NCEs
Cadila acquires skin treatment lotion Melgain® Trademark from ISSAR Pharma
ISSAR Pharma develops first-ever peptide molecule for skin care
Dr Reddy’s Laboratories Ltd (DRL) to emerge as one of the top five dermatology companies in India with their recent launch of Melgain licensed by ISSAR PHARMACEUTICALS